How to Select a Local Agent for Overseas Registration of POCT Products

To select a local agent for overseas registration of POCT products, manufacturers must first confirm whether the product falls within the target country's medical device regulatory scope and determine its risk classification. Requirements for local agents vary significantly across jurisdictions—some countries mandate a local license holder, while others only require an authorized representative for post-market surveillance. Start by evaluating the reusability of your existing technical documentation (performance validation, risk management, clinical evaluation) and the target country's registration pathway (e.g., EU IVDR classification, Thailand TFDA, Brazil ANVISA). Then assess potential agents on their ISO 13485 quality agreements, experience with similar products, ability to handle local language label and instruction conversions, and provisions for certificate control. Conduct thorough due diligence by checking the agent's registration records, client case studies, and regulatory communication capabilities.

Key Points

• Confirm whether the product is regulated as a medical device or IVD and its risk class.
• Local agent requirements differ: some countries require a local certificate holder; others only require an authorized representative.
• Reuse existing technical files (performance, risk management, clinical) where possible.
• Major risks: unauthorized certificate changes, delays due to insufficient capability, and failure in post-market obligations.
• Prepare a checklist covering quality agreements, product experience, label localization, and certificate control.
• For multi-country registration, consider a regional agent to reduce duplication.
• Due diligence is critical—check registrations, references, and regulatory communication skills.

Applicable Scenarios and Core Questions

Companies searching for this topic often need practical guidance on whether their existing documents support the target market application, whether a local agent or authorized representative is required, why timelines extend, and what issues affect launch plans. This involves product classification, registration route, evidence chain, label localization, and post-market responsibilities.

If entering multiple GHWP member states or markets in Southeast Asia, the Middle East, or Latin America, a single-country answer is insufficient. It is better to create a reusable core technical file and localize it per country.

Registration Decision Logic

First, determine if the product falls under the target country's medical device or IVD regulation. For example, a home-use POCT may be considered a medical device in some countries and an IVD in others. Second, identify the risk class (e.g., EU Class A-D, Southeast Asia A-B-C-D) to decide the registration path: self-declaration or notified body review. Third, evaluate existing compliance foundations: do you have NMPA, CE, FDA, or MDSAP certificates? Are your technical files (design history, risk management) sufficient? Fourth, confirm local agent needs: must the agent hold the certificate? Does the agent need to handle changes, renewals, and post-market activities?

For multi-country registrations, core technical files (performance evaluation, stability data) can be reused, but labels, IFUs, and clinical evaluation (e.g., local epidemiological data) need localization. Agents typically submit applications, handle regulatory inquiries, and assist in post-market surveillance.

Documentation and Evidence

Common documents include product description, model matrix, intended use, classification rationale, ISO 13485 or applicable QMS certificate, technical files, performance validation reports, risk management files, clinical evaluation or evidence, labels and IFUs, authorization letters, existing registration certificates, manufacturer declarations, and post-market surveillance data.

Quality matters more than quantity. Claims in the IFU, test reports, clinical evidence, risk management conclusions, labels, and application forms must support each other. Regulators assess whether the product is safe, effective, and traceable for the intended use.

Common Mistakes

• Submitting NMPA documents directly translated without restructuring for the target market.
• Too many models with insufficient test or clinical coverage.
• Choosing a local agent based only on sales support, not regulatory responsibility.
• Inconsistency between labels, IFUs, marketing materials, and registration dossiers.
• Failing to plan for document reuse across countries, increasing cost and time.

Preparation Checklist

• Verify whether the target country mandates a local agent and if the manufacturer can appoint one (e.g., EU Authorized Representative).
• Review the agent's qualifications: business license, ISO 13485 (not mandatory but a plus), and past registration approvals for similar products.
• Request a timeline and fee structure (registration, annual fees, change fees).
• In the agreement, define certificate ownership: the manufacturer should be the certificate owner; the agent is only a local contact.
• Include confidentiality, data protection, and obligation to inform of regulatory changes.
• Ensure the agent provides post-market support: adverse event reporting, label update processes, annual fee payment.

AIMEILI Regulatory Interpretation and Business Impact

The most common misjudgment is considering the agent as merely a 'document translator' and underestimating the agent's impact on the registration pathway. We recommend a regulatory gap analysis early in the project to identify reusable files and locally generated data (e.g., local clinical data, toxicology tests). For multi-country registration, choosing a regional agent (e.g., a Thailand agent covering ASEAN) significantly reduces coordination costs.

Certificate control is critical: the manufacturer must remain the certificate owner; the agent is an appointed party. If changes or renewals depend on the agent and the agent's business is interrupted, the certificate could lapse. Therefore, the contract should include the right for the manufacturer to communicate directly with regulators and transition clauses if the agent changes. Post-market maintenance is not optional; it is a core criterion when selecting an agent.

Follow-up Questions

I already have a CE IVDR certificate. Do I still need a local agent for Southeast Asian registration?

Yes, most Southeast Asian countries (e.g., Thailand, Indonesia, Malaysia, Philippines) require a local license holder or importer as the applicant. Even with a CE certificate, you must submit through a local agent. Your CE technical files can be used as a base, with the agent assisting translation and format conversion.

Can one local agent represent multiple companies with similar products? Is there a conflict of interest?

It is possible, but evaluate the agent's number of clients and focus. If the agent represents competing products, include information isolation clauses and audit the agent's independence regularly. Choose an agent specializing in medical devices or a specific product category to reduce risk.

What if the local agent exits or closes mid-registration?

Define exit mechanisms in the contract, including advance notice (e.g., 6 months), return of technical documents, and certificate transfer. Maintain a backup list of agents and ensure your company's contact information is complete in the original application so regulators can reach you directly.

Implementation Recommendations

Break the task into five parts: regulatory determination, documentation preparation, evidence reuse, localization, and post-market maintenance. This allows early identification of gaps and ensures sales, R&D, quality, and regulatory teams share the same understanding.

If entering multiple markets, create a unified core technical file first, then add country-specific authorizations, labels, languages, forms, and agent information. Efficiency depends on a consistent upfront documentation framework, not just speed in one country.

Quality System and Evidence Consistency

Regulators check consistency between the manufacturer name, production address, product scope, certificate validity, applicable standards, and technical files. If the ISO 13485 scope does not match the product, or if production address, models, IFU versions differ from test reports, you may be asked for clarification. Create an evidence consistency table that maps product name, model, intended use, standards, test report numbers, clinical evaluation conclusions, risk management versions, label versions, and QMS certificates.

Localization and Agent Responsibilities

You must clarify whether the local partner only submits documents or also handles regulatory communication, certificate maintenance, adverse event reporting, change applications, and renewal reminders. Labels and IFUs cannot be simply translated. Verify language requirements, claim boundaries, warnings, storage/transport conditions, UDI or traceability, importer information, authorized representative details, and after-sales contact. For companies with CE, FDA, NMPA, or other market data, localization means converting reusable evidence into the target country's preferred structure.

Post-Market Maintenance and Long-Term Planning

Registration does not end compliance work. Maintain certificate validity, change records, distributor authorizations, complaint handling, adverse event reports, recalls, label versions, and regulatory updates. Many companies invest heavily in getting the certificate but ignore post-market obligations. A change of production address, model extension, or IFU update can disconnect the certificate from market sales. AIMEILI advises managing this as an annual international registration plan: set market priorities, build a reusable data package and gap list, and schedule submissions, corrections, post-market maintenance, and renewals.

Note: This article is based on AIMEILI's registration practice database, international medical device registration knowledge base, and publicly available regulatory information. Specific projects should be based on the latest requirements of the target country's regulatory authority and the product dossier.